Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies
Request a Quote


High quality DMPK studies are at the heart of a successful drug discovery project. Done right, they can have a substantial impact on the development timeline, total cost of the project, and quality of the molecules that progress to the clinic.

At Sygnature we have built a DMPK team with a wealth of drug discovery experience. This enables us to do more than just deliver accurate DMPK data: we provide expert analysis and interpretation of the results. This is a key feature in helping drive your project forward.

We offer an extensive range of validated in silico, in vitro and in vivo DMPK services for drug discovery, backed up by a comprehensive portfolio of analytical techniques. We can design flexible DMPK screening cascades to support medicinal chemistry programmes, including bespoke method development.

Working closely with Chemistry and Bioscience, our approach is one of collaboration, partnering with clients to develop a greater understanding of the target and the properties that a successful drug should have. Expert guidance and problem-solving suggestions from our experienced team will help you optimise potential drug molecules, increasing the likelihood of success.

DMPK Services:


Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

DMPK Services

Physicochemical Profiling

It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.


In Vitro ADME

The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development. 


In Vivo Pharmacokinetics

At Sygnature Discovery we offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS


PK and Bioanalysis

Sygnature Discovery offers a range of pharmacokinetics, bioanalysis and metabolite identification services adapted to each project needs. Our experience is complemented with a suite of state-of-the art bioanalytical and metabolic identification mass spectrometry equipment.


Metabolite Identification and Biotransformation

Sygnature Discovery offers a range of metabolite identification and biotransformation services adapted to each project needs. Our experience is complemented with a suite of state-of-the art mass spectrometry equipment.


IVIVE and Human PK Predictions

The DMPK team at Sygnature Discovery has several years of experience in PK modelling and simulation. In complement to our in vitro and in vivo ADME laboratory-based services, we also offer several IVIVE and PK prediction packages to support the various stages of the drug discovery process from screening, to selection and to election of a pre-clinical drug candidate.


DMPK Consultancy

Sygnature Discovery offers a range of DMPK consultancy services to drug discovery research teams within the academic, pharmaceutical, biotechnology, charity and CRO sectors as well as to life science venture capital funds.


Discovery Toxicology

The Discovery Toxicology group at Sygnature will work in partnership with clients and side by side with chemists, computational chemists, and DMPK scientists, to provide a broad range of assays and expertise to identify and eliminate liabilities earlier during the discovery process.


Latest News

View All

Sygnature Discovery Adopts OpenEye’s Orion™ Platform to…

Sygnature Discovery shortlisted for BioNow Company of…

Sygnature upgrades western blotting capability with Jess…

Dr Paul Overton becomes Chief Commercial Officer…